NUP50: A Potential Drug Target and Biomarker (G10762)

Target Name: NUP50

NCBI ID: G10762

NUP50

NUP50: A Potential Drug Target and Biomarker

Nucleoporin Nup50, also known as NUP50, is a protein that is expressed in various cell types of the human body, including epithelial, endothelial, and immune cells. It is a member of the nucleoporin family, which is a family of proteins that play a critical role in the regulation of nuclear transport and the association with various diseases, including cancer.

The discovery and characterization of Nup50 dates back to the 1990s, when researchers identified it as a protein that was expressed in various types of cancer cells. Since then, studies have shown that Nup50 is involved in various cellular processes, including cell signaling, cell adhesion, and cell survival.

One of the key functions of Nup50 is its role in cell signaling. Nup50 has been shown to play a role in the regulation of T cell development and function, as well as in the regulation of cell adhesion and migration. Nup50 has also been shown to play a role in the regulation of angiogenesis, the process by which new blood vessels are formed.

In addition to its role in cell signaling, Nup50 has also been shown to be involved in cell adhesion and survival. Nup50 has been shown to play a role in the regulation of cell-cell adhesion, as well as in the regulation of cell survival and apoptosis.

The potential drug targeting of Nup50 comes from its role in various cellular processes and its involvement in cancer. Nup50 has been shown to be involved in the regulation of cancer cell growth, and has been identified as a potential drug target for various types of cancer, including breast, ovarian, and prostate cancers.

In addition to its potential as a drug target, Nup50 has also been identified as a potential biomarker for cancer. Nup50 has been shown to be expressed in various types of cancer cells, and has been used as a biomarker for cancer diagnosis and monitoring.

The identification of Nup50 as a potential drug target and biomarker has implications for the development of new treatments for various types of cancer. By targeting Nup50 with drugs, researchers hope to inhibit its role in cell signaling and cell adhesion, and to inhibit its regulation of cancer cell growth and survival.

In conclusion, Nup50 is a protein that has been identified as a potential drug target and biomarker for cancer. Its role in cell signaling, cell adhesion, and cell survival makes it an attractive target for drugs that are designed to inhibit its function. Further research is needed to fully understand the role of Nup50 in cancer and to develop new treatments that can effectively target it.

Protein Name: Nucleoporin 50

Functions: Component of the nuclear pore complex that has a direct role in nuclear protein import (PubMed:20016008). Actively displaces NLSs from importin-alpha, and facilitates disassembly of the importin-alpha:beta-cargo complex and importin recycling (PubMed:20016008). Interacts with regulatory proteins of cell cycle progression including CDKN1B (By similarity). This interaction is required for correct intracellular transport and degradation of CDKN1B (By similarity)

The "NUP50 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NUP50 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets